Clinical Impact of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Carried Out for Non-Medicare Eligible Indications in Australia: A Prospective Study

Clin Oncol (R Coll Radiol). 2015 Dec;27(12):753-4. doi: 10.1016/j.clon.2015.08.005. Epub 2015 Sep 4.

Authors

P Lin¹, E Stoakes², A Scott², S Sam², A Chicco²

Affiliations

¹ Department of Nuclear Medicine and PET, Liverpool Hospital, Australia; University of New South Wales, Sydney, Australia; University of Western Sydney, Australia.
² Department of Nuclear Medicine and PET, Liverpool Hospital, Australia.

PMID: 26345249
DOI: 10.1016/j.clon.2015.08.005

No abstract available

Publication types

Letter

MeSH terms

Australia
Fluorodeoxyglucose F18*
Humans
Medicare / statistics & numerical data*
Neoplasms / diagnostic imaging*
Neoplasms / economics
Positron-Emission Tomography / methods*
Prospective Studies
Radiopharmaceuticals
Tomography, X-Ray Computed / methods*
United States

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18